Skip to main navigation Skip to search Skip to main content

Visceral leishmaniasis IgG1 rapid monitoring of cure vs. relapse, and potential for diagnosis of post kala-azar dermal leishmaniasis

  • Tegwen Marlais
  • , Tapan Bhattacharyya
  • , Om Prakash Singh
  • , Pascal Mertens
  • , Quentin Gilleman
  • , Caroline Thunissen
  • , Bruno C. Bremer Hinckel
  • , Callum Pearson
  • , Bathsheba L. Gardner
  • , Stephanie Airs
  • , Marianne de la Roche
  • , Kiera Hayes
  • , Hannah Hafezi
  • , Andrew K. Falconar
  • , Osama Eisa
  • , Alfarazdeg Saad
  • , Basudha Khanal
  • , Narayan Raj Bhattarai
  • , Suman Rijal
  • , Marleen Boelaert
  • Sayda El-Safi, Shyam Sundar, Michael A. Miles

    Research output: Contribution to journalA1: Peer-reviewed journal articlespeer-review

    17 Downloads (Pure)

    Abstract

    Background: There is a recognized need for an improved diagnostic test to assess post-chemotherapeutic treatment outcome in visceral leishmaniasis (VL) and to diagnose post kala-azar dermal leishmaniasis (PKDL). We previously demonstrated by ELISA and a prototype novel rapid diagnostic test (RDT), that high anti-Leishmania IgG1 is associated with post-treatment relapse versus cure in VL.

    Methodology: Here, we further evaluate this novel, low-cost RDT, named VL Sero K-SeT, and ELISA for monitoring IgG1 levels in VL patients after treatment. IgG1 levels against L. donovani lysate were determined. We applied these assays to Indian sera from cured VL at 6 months post treatment as well as to relapse and PKDL patients. Sudanese sera from pre- and post-treatment and relapse were also tested.

    Results: Of 104 paired Indian sera taken before and after treatment for VL, when deemed clinically cured, 81 (77.9%) were positive by VL Sero K-SeT before treatment; by 6 months, 68 of these 81 (84.0%) had a negative or reduced RDT test line intensity. ELISAs differed in positivity rate between pre- and post-treatment (p = 0.0162). Twenty eight of 33 (84.8%) Indian samples taken at diagnosis of relapse were RDT positive. A comparison of Indian VL Sero K-SeT data from patients deemed cured and relapsed confirmed that there was a significant difference (p <0.0001) in positivity rate for the two groups using this RDT. Ten of 17 (58.8%) Sudanese sera went from positive to negative or decreased VL Sero K-SeT at the end of 11-30 days of treatment. Forty nine of 63 (77.8%) PKDL samples from India were positive by VL Sero K-SeT.

    Conclusion: We have further shown the relevance of IgG1 in determining clinical status in VL patients. A positive VL Sero K-SeT may also be helpful in supporting diagnosis of PKDL. With further refinement, such as the use of specific antigens, the VL Sero K-SeT and/or IgG1 ELISA may be adjuncts to current VL control programmes.

    Original languageEnglish
    Article number427
    JournalFrontiers in Cellular and Infection Microbiology
    Volume8
    Number of pages10
    ISSN2235-2988
    DOIs
    Publication statusPublished - 2018

    Keywords

    • visceral leishmaniasis
    • serology
    • treatment
    • relapse
    • cure
    • IgG1
    • RDT
    • PKDL
    • SEROLOGICAL MARKERS
    • NATURAL-HISTORY
    • BIHAR
    • INFECTION
    • MILTEFOSINE
    • HOUSEHOLDS
    • INFANTUM
    • AREAS
    • TESTS

    Fingerprint

    Dive into the research topics of 'Visceral leishmaniasis IgG1 rapid monitoring of cure vs. relapse, and potential for diagnosis of post kala-azar dermal leishmaniasis'. Together they form a unique fingerprint.

    Cite this